Keywords: xention, acquires, developmental, drug, oab, cambridge, uk-based

Xention acquires developmental drug for OAB

Article | 11 December 2006

Cambridge, UK-based Xention says that it has acquired exclusive rights to develop certain ion channel modulators with potential applications in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Go to company listing